Novavax’s 2024-2025 COVID-19 Vaccine Receives EUA for Use in the U.S.
Novavax, Inc. (Nasdaq: NVAX), a leading company in protein-based vaccines, has announced that its latest COVID-19 vaccine, the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705), ... Read More
Is US facing new COVID-19 nightmare? KP.2 variant pushes hospitalization rates to record levels
The United States is grappling with the most severe COVID-19 surge since 2022, characterised by a sharp increase in hospitalisation rates and intensified viral activity. ... Read More
Novavax reports success for NVX-CoV2373 in pediatric group of phase 3 trial
Novavax said that its Covid-19 vaccine NVX-CoV2373 achieved its primary effectiveness endpoint in the pediatric expansion of its phase 3 PREVENT-19 trial. According to the ... Read More
Novavax begins phase 3 trial of NVX-CoV2373 COVID-19 vaccine candidate
Novavax has initiated its first phase 3 clinical trial to assess the efficacy, safety, and immunogenicity of its NVX-CoV2373 COVID-19 vaccine candidate. The US vaccine ... Read More
Takeda strikes deal to bring Novavax’ NVX‑CoV2373 COVID-19 vaccine to Japan
US-based pharma company Novavax and Takeda Pharmaceutical have joined forces for the development, manufacturing, and commercialization of NVX‑CoV2373, the former's COVID‑19 vaccine candidate, in Japan. ... Read More
Novavax NVX-CoV2373 COVID-19 vaccine candidate to be manufactured by FDB
Novavax has signed an agreement with FUJIFILM Diosynth Biotechnologies (FDB), a US-based contract development and manufacturing organization (CDMO), for the manufacturing of bulk drug substance ... Read More